Century Therapeutics Announces Closing of Initial Public Offering
Century Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
PHILADELPHIA, June 22, 2021 (GLOBE NEWSWIRE) – Century Therapeutics (NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in immuno-oncology, today announced the closing of its initial public offering of 12,132,500 shares of its common stock at a public offering price of $20.00 per share, which includes the full exercise by the underwriters of their option to purchase 1,582,500 additional shares of common stock. The aggregate gross proceeds from the offering, before deducting underwriting discounts and commissions and other offering expenses payable by Century, were approximately $242.7 million. All the shares of common stock were offered by Century.
J.P. Morgan, BofA Securities, SVB Leerink and Piper Sandler acted as joint book-running managers for the offering.
A registration statement relating to the shares being sold in this offering was filed with the Securities and Exchange Commission and became effective on June 17, 2021. The offering was made only by means of a prospectus. Copies of the final prospectus may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at firstname.lastname@example.org, or by telephone at (866) 803-9204; BofA Securities, NC1-004-03-43, 200 North College Street, 3rd Floor, Charlotte, NC 28255-0001, Attention: Prospectus Department, or by email at email@example.com, 1-800-294-1322; SVB Leerink LLC, Attention: Syndicate Department, One Federal Street, 37th Floor, Boston, MA 02110, by telephone at 1-800-808-7525 ex. 6105 or by email at firstname.lastname@example.org; and Piper Sandler & Co., Attn: Prospectus Department, 800 Nicollet Mall, J12S03, Minneapolis, Minnesota 55402, by telephone at (800) 747-3924 or by email at email@example.com.
This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.
About Century Therapeutics
Century Therapeutics (NASDAQ: IPSC) is harnessing the power of adult stem cells to develop curative cell therapy products for cancer that we believe will allow us to overcome the limitations of first-generation cell therapies. Our genetically engineered, iPSC-derived iNK and iT cell products are designed to specifically target hematologic and solid tumor cancers. We believe our commitment to developing off-the-shelf cell therapies will expand patient access and provides an unparalleled opportunity to advance the course of cancer care.